Ameren’s Own Analysis Shows Gas Plant Won’t Fix Midwest Power Gap, Adding Execution Risk

What happened

Ameren’s planned 800 MW Big Hollow gas plant—a centerpiece of its $27.4 billion capex plan—is insufficient to meet surging data center demand in the Midwest, the company’s own analysis shows ahead of a key regulatory approval in August 2026. The revelation confirms that the regional power crunch outpaces current build-out plans, potentially requiring additional generation or transmission beyond the already sizable investment program. This shortfall also complicates Ameren’s pending large-load tariff proposal, raising the specter of political pushback if ratepayers are asked to fund an incomplete fix. For investors, the news adds a layer of execution risk to the growth story, as approval delays or the need for further capital raising could strain an already leveraged balance sheet and ongoing equity dilution. While the underlying regulated monopoly remains intact, the mismatch between supply and demand underscores the fragility of near-term earnings visibility and the plan’s adequacy.

Implication

Longer term, the persistent capacity deficit strengthens the need for further rate-base expansion, but it intensifies scrutiny on Ameren’s execution and balance sheet management. If regulators support accelerated investment with cost recovery, earnings growth could reaccelerate, though equity issuance needs will likely rise. Conversely, any disallowance of additional capex or political resistance to funding insufficient solutions could cap returns and erode the moat’s durability. Investors must watch whether Ameren can convert this shortfall into accretive rate-base growth without a credit downgrade or dilution spiral. The situation may tilt the risk-reward from steady compounding toward a more binary outcome dependent on upcoming regulatory decisions.

Thesis delta

The news challenges the assumption that the Big Hollow plant would adequately address demand, instead implying either a longer runway for additional projects or risk that current plans face skepticism. While the core thesis of a steady regulated compounder with visible rate-base growth remains, the margin of safety is narrowing as execution and regulatory risks rise. This reinforces the WAIT stance and raises the possibility of a shift to POTENTIAL SELL if the approval process reveals deeper funding gaps without commensurate regulatory support.